World's Best Scientists 2026 revealed!
Award Badge
Medicine
Netherlands
2023

D-Index & Metrics

Medicine

D-Index
137
Citations
103403
World Ranking
1859
National Ranking
70

Research.com Recognitions

  • 2023 - Research.com Medicine in Netherlands Leader Award
  • 2011 - Royal Netherlands Academy of Arts and Sciences

Overview

Jaap Verweij is affiliated with Erasmus University Rotterdam in the Netherlands, where the primary focus of their research is in the field of Medicine, with particular expertise in Oncology, Cancer Research, and Epidemiology. Their work spans a range of subfields such as Economics and Econometrics, Pulmonary and Respiratory Medicine, and several intersecting areas of cancer research and health systems analysis.

The scientist's research addresses topics including Cancer Genomics and Diagnostics, Cervical Cancer and HPV Research, Health Systems and Economic Evaluations, Genetic factors in colorectal cancer, Colorectal and Anal Carcinomas, Economic and Financial Impacts of Cancer, and Pharmaceutical Economics and Policy. This breadth of topics indicates engagement with both biomedical and systemic approaches to cancer and healthcare.

Key recent publications by Verweij demonstrate a focus on cancer biology and health outcomes:

  • "Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site," 2020, British Journal of Cancer
  • "Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe," 2020, Cancers
  • "Empowering effective biomarker-driven precision oncology: A call to action," 2024, European Journal of Cancer
  • "Ektacytometry Analysis of Post-splenectomy Red Blood Cell Properties Identifies Cell Membrane Stability Test as a Novel Biomarker of Membrane Health in Hereditary Spherocytosis," 2021, Frontiers in Physiology
  • "StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs)," 2024, Journal of Clinical Oncology

Frequent collaborators in Verweij's work include B. Dekeyser, Barend J. Sikkema, Peter de Bruijn, F. Wastelin, and François Zammit, each contributing to multiple publications. This suggests a consistent research network supporting studies across oncology, pharmacology, and related biomedical fields.

Verweij has published extensively in recognized venues such as the British Journal of Cancer, European Journal of Cancer, Cancers, Frontiers in Physiology, and the Journal of Clinical Oncology. These publication venues reflect the multidisciplinary nature of their research spanning clinical oncology, physiology, and cancer policy evaluation.

In recognition of contributions to science, Jaap Verweij was awarded membership by the Royal Netherlands Academy of Arts and Sciences in 2011. This accolade indicates peer recognition within the Netherlands scientific community.

Best Publications

  • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

    Elizabeth Eisenhauer;Patrick Therasse;Jan Bogaerts;L.H. Schwartz

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

    Hans Gelderblom;Jaap Verweij;Kees Nooter;Alex Sparreboom

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

    Allan T van Oosterom;Ian Judson;Jaap Verweij;Sigrid Stroobants

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

    Albert J ten Tije;Jaap Verweij;Walter J Loos;Alex Sparreboom;Alex Sparreboom

  • Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

    Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

    Rolf D Issels;Lars H Lindner;Jaap Verweij;Peter Wust

  • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

    A Santoro;T Tursz;H Mouridsen;Jaap Verweij

  • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

    Andrea Ardizzoni;Heine Hansen;Per Dombernowsky;Teresa Gamucci

  • Soft Tissue Sarcomas of Adults State of the Translational Science

    Ernest C. Borden;Laurence H. Baker;Robert S. Bell;Vivien Bramwell

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Effects of St. John's Wort on Irinotecan Metabolism

    Ron H. J. Mathijssen;Jaap Verweij;Peter de Bruijn;Walter J. Loos

  • Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

    G J Creemers;G Bolis;M Gore;G Scarfone

Frequent Co-Authors

Alex Sparreboom
Alex Sparreboom The Ohio State University
Ron H.J. Mathijssen
Ron H.J. Mathijssen Erasmus University Rotterdam
Stefan Sleijfer
Stefan Sleijfer Erasmus University Rotterdam
Ian Judson
Ian Judson Institute of Cancer Research
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Paolo G. Casali
Paolo G. Casali University of Milan
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education options can open many doors for aspiring healthcare professionals. For registered nurses looking to advance their credentials without breaking the bank, the cheapest rn to bsn online programs are worth considering. These affordable BSN programs provide flexibility and allow working nurses to continue their education on their own schedule.

Those without a nursing background who are aiming for advanced roles may benefit from direct entry msn programs for non nurses online. These programs are designed for individuals with a bachelor's degree in another field, helping them make a swift transition into nursing.

If you’re just starting your journey and seeking accessible entry points, learning about the easiest rn program can guide you towards schools with higher acceptance rates and less competitive admissions.

Beyond nursing, the healthcare field also needs skilled professionals in administration. Accredited medical billing and coding online schools with financial aid can help students join this in-demand sector, all from the convenience of home.

Best Scientists Citing Jaap Verweij

Trending Scientists

Recently Published Articles